The Triumph of Hope Over Science
By Mark Derr,
New York Times
| 02. 24. 2004
After I was diagnosed with Parkinson's disease two years ago,
at the relatively young age of 52, I read everything I could
about the condition's usual "progression" — an
odd word for degeneration. The worst-case prognosis is grim:
a long slide into physical and mental incapacity.
That is not going to happen to me, I said, as I began measuring
my physical decline. I am young enough that I may be able to
benefit from advances in medicine, especially in brain research.
Maybe with new medications I would be able to put off taking
L-dopa, the best drug for Parkinson's but one that loses its
effectiveness over time. Surely better treatments will become
available, I told myself.
So why didn't I welcome the news that researchers in South
Korea were able to clone a human embryo and extract viable stem
cells from it? After all, one of the researchers said their
goal was "not to clone humans, but to understand the causes
of diseases" — and one of the diseases named most
often was Parkinson's. Scientists say they may one...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...